169 related articles for article (PubMed ID: 27770539)
1. Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice.
Zhu X; Zhang C; Fan Q; Liu X; Yang G; Jiang Y; Wang L
Med Sci Monit; 2016 Oct; 22():3902-3909. PubMed ID: 27770539
[TBL] [Abstract][Full Text] [Related]
2. Effect of losartan on the glomerular protein expression profile of type 2 diabetic KKAy mice.
Fan QL; Yang G; Liu XD; Ma JF; Feng JM; Jiang Y; Wang LN
J Nephrol; 2013; 26(3):517-26. PubMed ID: 22684654
[TBL] [Abstract][Full Text] [Related]
3. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profile in glomeruli of type-2 diabetic KKAy mice using 2-dimensional differential gel electrophoresis.
Liu X; Yang G; Fan Q; Wang L
Med Sci Monit; 2014 Dec; 20():2705-13. PubMed ID: 25515740
[TBL] [Abstract][Full Text] [Related]
5. Low-protein diet supplemented with ketoacids delays the progression of diabetic nephropathy by inhibiting oxidative stress in the KKAy mice model.
Liu D; Wu M; Li L; Gao X; Yang B; Mei S; Fu L; Mei C
Br J Nutr; 2018 Jan; 119(1):22-29. PubMed ID: 29208058
[TBL] [Abstract][Full Text] [Related]
6. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.
Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336
[TBL] [Abstract][Full Text] [Related]
7. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
Reddy MA; Sumanth P; Lanting L; Yuan H; Wang M; Mar D; Alpers CE; Bomsztyk K; Natarajan R
Kidney Int; 2014 Feb; 85(2):362-73. PubMed ID: 24088954
[TBL] [Abstract][Full Text] [Related]
8. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
10. Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease.
Liu Y; Li H; Liu J; Han P; Li X; Bai H; Zhang C; Sun X; Teng Y; Zhang Y; Yuan X; Chu Y; Zhao B
J Am Soc Nephrol; 2017 Dec; 28(12):3627-3638. PubMed ID: 28923913
[TBL] [Abstract][Full Text] [Related]
11. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy.
Hou X; Tian J; Geng J; Li X; Tang X; Zhang J; Bai X
Oncotarget; 2016 Jul; 7(30):47760-47776. PubMed ID: 27351287
[TBL] [Abstract][Full Text] [Related]
13. Tectorigenin attenuates diabetic nephropathy by improving vascular endothelium dysfunction through activating AdipoR1/2 pathway.
Yang S; Ma C; Wu H; Zhang H; Yuan F; Yang G; Yang Q; Jia L; Liang Z; Kang L
Pharmacol Res; 2020 Mar; 153():104678. PubMed ID: 32014572
[TBL] [Abstract][Full Text] [Related]
14. Effect of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from Averrhoa carambola L. (Oxalidaceae) roots, on advanced glycation end-product-mediated renal injury in type 2 diabetic KKAy mice.
Zheng N; Lin X; Wen Q; Kintoko ; Zhang S; Huang J; Xu X; Huang R
Toxicol Lett; 2013 May; 219(1):77-84. PubMed ID: 23500658
[TBL] [Abstract][Full Text] [Related]
15. Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.
Yang G; Zhao Z; Zhang X; Wu A; Huang Y; Miao Y; Yang M
Drug Des Devel Ther; 2017; 11():1065-1079. PubMed ID: 28408805
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
Kölling M; Kaucsar T; Schauerte C; Hübner A; Dettling A; Park JK; Busch M; Wulff X; Meier M; Scherf K; Bukosza N; Szénási G; Godó M; Sharma A; Heuser M; Hamar P; Bang C; Haller H; Thum T; Lorenzen JM
Mol Ther; 2017 Jan; 25(1):165-180. PubMed ID: 28129112
[TBL] [Abstract][Full Text] [Related]
17. C66 ameliorates diabetic nephropathy in mice by both upregulating NRF2 function via increase in miR-200a and inhibiting miR-21.
Wu H; Kong L; Tan Y; Epstein PN; Zeng J; Gu J; Liang G; Kong M; Chen X; Miao L; Cai L
Diabetologia; 2016 Jul; 59(7):1558-1568. PubMed ID: 27115417
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-29a Attenuates Diabetic Glomerular Injury through Modulating Cannabinoid Receptor 1 Signaling.
Tung CW; Ho C; Hsu YC; Huang SC; Shih YH; Lin CL
Molecules; 2019 Jan; 24(2):. PubMed ID: 30642005
[TBL] [Abstract][Full Text] [Related]
19. miR-193a as a potential mediator of WT-1/synaptopodin in the renoprotective effect of Losartan on diabetic kidney.
Gao D; Yu P; Jing S; Yan C; Ding D; Qiao Y; Wu G
Can J Physiol Pharmacol; 2022 Jan; 100(1):26-34. PubMed ID: 34411489
[TBL] [Abstract][Full Text] [Related]
20. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis.
Eissa S; Matboli M; Bekhet MM
Biomed Pharmacother; 2016 Oct; 83():92-99. PubMed ID: 27470555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
